Clinical trials: Meniere Disease
Meniere's Disease
Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy
This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's…
- Trial name
- NCT00160238
- Testing
- Betahistine 24 mg bid (Betaserc)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Solvay Pharmaceuticals
Meniere's Disease
Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets
A multicenter, randomized, open-label clinical study with a concurrent control group to assess the effectiveness and safety of combined therapy with Isobide solution and Meniace tablets compared to monotherapy with Meniace…
- Trial name
- NCT02718846
- Testing
- Meniace, Isobide
- Volunteers
- 220 people
- Sponsor
- Alvogen Korea
Meniere's Disease
SPI-1005 for the Treatment of Patients With Meniere's Disease
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
- Trial name
- NCT03325790
- Testing
- 200mg SPI-1005 BID, 400mg SPI-1005 BID
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- AVERTS-2 (NCT02717442)
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease, Ménière's Disease
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
- Trial name
- NCT06859788
- Testing
- Ebselen
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere´s Disease
Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease
The purpose of this study is to evaluate the efficacy and safety of isosorbide oral solution compared with placebo in people with unilateral Meniere's disease.
- Trial name
- MD (NCT06765993)
- Testing
- Isosorbide oral solution
- Volunteers
- 234 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Meniere Disease
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- NCT03664674
- Testing
- OTO-104
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 148 people
- Sponsor
- Otonomy, Inc.
Tinnitus
Caroverin and Inner Ear Diseases
This trial is a randomized, double blind, placebo controlled study on patients suffering from inner ear diseases with tinnitus as a principal symptom.
- Trial name
- NCT01174979
- Testing
- Caroverin
- Where
- Austria
- Volunteers
- 170 people
- Sponsor
- Phafag AG
Meniere Disease, Vertigo
Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease
The purpose of this study is to evaluate the safety of APSLXR in participants with Meniere's disease or other Verigo of vestibular origin. Pharmacokinetics will also be evaluated in a small group.
- Conditions
- Meniere Disease, Vertigo, Vertigo Vestibular
- Trial name
- NCT04674735
- Testing
- APSLXR
- Sponsor
- Apsen Farmaceutica S.A.
Meniere's Disease
OTO-104 for Meniere's Disease
The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.
- Trial name
- NCT01084525
- Testing
- OTO-104 (steroid) 3 mg, OTO-104 (steroid) 12 mg
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease
Sildenafil For Meniere's Disease
Meniere's disease affects a person's sense of balance. An attack can last 20 minutes to 2 hours or longer. Symptoms include rotational vertigo, hearing loss, tinnitus and a sensation of fullness in the affected ear and may be…
- Trial name
- NCT00145483
- Testing
- Sildenafil
- Where
- 4 sites in Australia
- Volunteers
- 163 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Meniere Disease, Ménière
SPI-1005 for the Treatment of Meniere's Disease
The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial (RCT) with open-label extension study (OLE), of SPI-1005 in adult subjects with definite Meniere's disease with active symptoms within three…
- Trial name
- STOPMD-3 (NCT04677972)
- Testing
- Ebselen
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere's Disease
OTO-104 for the Treatment of Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- NCT01412177
- Testing
- OTO-104
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease
A 6-Month Extension Study of OTO-104 in Meniere's Disease
This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections.
- Trial name
- NCT02768662
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease, Meniere Disease
Expanded Access Protocol for SPI-1005
The purpose of this protocol is to facilitate expanded access ("compassionate use") of SPI-1005 to Meniere's disease (MD) or sudden sensorineural hearing loss (SSNHL) patients who cannot gain access through ongoing clinical…
- Conditions
- Meniere's Disease, Meniere Disease, Meniere´s Disease, Meniere's Disease Aggravated
- Trial name
- NCT07873281
- Testing
- Ebselen
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere's Disease
Open Label Study of OTO-104 in Subjects With Meniere's Disease
This is a 1-year, multicenter, Phase 2, open-label safety study in subjects with unilateral Meniere's disease. Subjects will receive 1 intratympanic (IT) injection of 12 mg OTO-104 at 3-month intervals for a total of 4 injections…
- Trial name
- NCT02740387
- Testing
- OTO-104
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- AVERTS-1 (NCT02612337)
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Otonomy, Inc.
Vertigo, BPPV
Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
The goal of this virtual clinical trial is to determine the effectiveness of two study devices in providing temporary relief to adults aged 18-70 who suffer from symptoms of chronic vestibular vertigo.
- Conditions
- Vertigo, BPPV, Meniere Disease, Labrynthitis
- Trial name
- NCT05960786
- Testing
- Otoband Experimental
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Otolith Labs
Meniere's Disease
A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom
This is a 2-part study of OTO-104 in subjects with unilateral Meniere's disease in the United Kingdom. The first part is a randomized, placebo-controlled study comparing the safety profile of 2 injections of OTO-104 or placebo…
- Trial name
- NCT02265393
- Testing
- OTO-104
- Where
- 15 sites in United Kingdom
- Volunteers
- 128 people
- Sponsor
- Otonomy, Inc.
Vertigo
Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting
This study seeks to gather data on the effect of a device, the OtoBand, in participants who have reported symptoms of vertigo, compared to the effect of using one of two sham devices.
- Trial name
- NCT04869020
- Testing
- Otoband
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Otolith Labs